References

helmholtzeyeinstitute

Российский офтальмологический журнал

Russian Ophthalmological Journal

2072-00762587-5760

Real time Publishers

10.21516/2072-0076-2018-11-2-95-101

helmholtzeyeinstitute-161

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

REVIEWS

БЕСКОНСЕРВАНТНАЯ ФОРМА ФИКСИРОВАННОЙ КОМБИНАЦИИ БИМАТОПРОСТА И ТИМОЛОЛА В ПОВЫШЕНИИ КОМПЛАЕНСА И ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМОЙ

PRESERVATIVE-FREE FIXED COMBINATION OF BIMATOPROST AND TIMOLOL IN THE EVOLUTION OF COMPLIANCE AND TREATMENT EFFECTIVENESS IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA

Лоскутов

И. А.

Loskoutov

I. A.

noemail@neicon.ru

Корнеева

А. В.

Korneeva

A. V.

noemail@neicon.ru

Офтальмологическое отделение Научно-практического центра ООО «РЖД», МоскваРоссияScientific and clinical center of Russian railways, 84, Moscow, RussiaRussian Federation

ООО «Три-З», МоскваРоссияTri-Z Clinical Centre, Moscow, RussiaRussian Federation

2018

03102018

11295101

2018

Лоскутов И.А., Корнеева А.В.

Loskoutov I.A., Korneeva A.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://roj.igb.ru/jour/article/view/161

Цель обзора - анализ данных новейших клинических исследований эффективности и безопасности фиксированных комбинаций как средства первоочередного выбора в терапии пациентов с первичной открытоугольной глаукомой. Анализируются данные о применении фиксированной комбинации биматопроста 0,03% и тимолола 0,5%, а также влияние применения данной фиксированной комбинации без консерванта на повышение приверженности к лечению, сохранение зрительных функций и повышение качества жизни пациентов на всех стадиях глаукомного процесса. Для цитирования: Лоскутов И.А., Корнеева А.В. Бесконсервантная форма фиксированной комбинации биматопроста и тимолола в повышении комплаенса и эффективности лечения пациентов с первичной открытоугольной глаукомой. Российский офтальмологический журнал. 2018; 11(2): 95-101. doi: 10.21516/2072-0076-2018-11-2-95-101.

The purpose of the review is to analyze the recent clinical research data concerning the efficacy and safety of fixed combinations as a first-choice therapy of patients with all stages of primary open-angle glaucoma. Application results of a fixed combination of Bimatoprost 0.03 % and Timolol 0.5 % are analyzed. The impact of preservative-free fixed combination usage on increasing the compliance, protection of visual functions and improving life quality at different stages of the glaucomatous process. For citation: Loskoutov I.A., Korneeva A.V. Preservative-free fixed combination of Bimatoprost and Timolol in the evolution of compliance and treatment effectiveness in patients with primary open-angle glaucoma. Russian ophthalmological journal. 2018; 11 (2): 95-101. doi: 10.21516/2072-0076-2018-11-2-95-101 (In Russian).

первичная открытоугольная глаукомабиматопросттимололфиксированная комбинациябесконсервантная формаprimary open-angle glaucomaBimatoprostTimololpreservative-free fixed combination

References1

Freeman E.E., Munoz B., West S.K., Jampel H.D., Friedman D.S. Glaucoma and quality of life: the Salisbury eye evaluation. Ophthalmol. 2008; 115(2): 233-38. doi.org/10.1016/j.ophtha.2007.04.050

European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi.org/10.1136/bjophthalmol-2016-egsguideline.001

Pillunat L.E., Eschstruth P., Haesemeyer S., Theren U., et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clinic. Ophthalmol. 2016; 10: 1759-65. doi.org/10.2147/opth.s103084

Hyman L.G., Komaroff E., Heijl A., Bengtsson B., Leske M.C. Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmol. 2005; 112(9): 1505-13. doi.org/10.1016/j.ophtha.2005.03.028

Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmol. 2008; 115: 1557-65. doi:10.1016/j. ophtha.2008.02.005

Gillespie B.W., Musch D.C., Guire K.E., Mills R.P., et al. CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group. The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest. Ophthalmol. Vis. Sci. 2003; 44: 2613-20. doi.org/10.1167/iovs.02-0543

Chauhan B.C., Mikelberg F.S., Balaszi A.G., LeBlanc R.P., et al. Canadian Glaucoma Study Group; Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch. Ophthalmol. 2008; 126: 1030-36. doi:10.1001/ archopht.126.8.1030

Adatia F.A., Damji K.F. Chronic open-angle glaucoma. Review for primary care physicians. Can. Fam. Physician. 2005; 51: 1229-37.

Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert. Op. in Emerg. Drugs. 2011; 16(2): 293-307. doi.org/10.1517/14728214.2011.563733

Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol. 2002; 120(10): 1268-79. doi.org/10.1001/archopht.120.10.1268

Resnikoff S., Pascolini D., Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11): 844-51. doi.org/10.2471/blt.07.041210

Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006; 90(3): 262-67. doi.org/10.1136/bjo.2005.081224

Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G, et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385: 1295-1304. doi: 10.1016/S0140-6736(14)62111-5

van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmol. 2005; 112: 1177-85. doi.org/10.1016/j.ophtha.2005.01.042

Konstas A.G., Maltezos A.C., Gandi, S., Hudgins, A.C., Stewart, W.C. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 1999; 128: 15-20. doi.org/10.1016/s0002-9394(99)00073-2

Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials. J. Glaucoma. 2008; 17: 667-73. doi:10.1097/IJG. 0B013e3181666557

Inoue K., Shiokawa M., Fujimoto T., Tomita G. Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma. Clin. Ophthalmol. 2014; 8: 1179-83. doi.org/10.2147/opth.s60538

Sato S., Hirooka K., Baba T., Mizote M., et al. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. J. Ocul. Pharmacol. Ther. 2011; 27: 499-502. doi.org/10.1089/jop.2011.0020

Ciancaglini M., Caprineto P., Agnifili L., Nubile M., et al. A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma. European J. Ophthalmol. 2009; 19(4): 584-600. doi.org/10.1177/112067210901900412

Pohjanpelto P. Long-term prognosis of visual field in glaucoma simplex and glaucoma capsulare. Acta Ophthalmol. (Copenh). 1985; 63: 418-23.

Konstas A.G., Mantziris D.A., Stewart W.C. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch. Ophthalmol. 1997; 115: 182-5. doi.org/10.1001/archopht.1997.01100150184006

Takmaz T., Can I., Gurdal C., Kurkcuoglu P., et al. Effect of bimatoprost on intraocular pressure after phacoemulsification in eyes with exfoliation syndrome. Acta Ophthalmol. Scand. 2007; 85(3): 262-6. doi.org/10.1111/j.1600-0420.2006.00835.x

Bömer T.G., Lagreze W-D.A, Funk J. Intraocular pressure rise after phacoemulsiﬁcation with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon’s experience. Br. J. Ophthalmol. 1998; 12: 809-13. doi.org/10.1136/bjo.79.9.809

Prum B.E., Rosenberg L.F., Gedde S.J. et al. Primary open-angle glaucoma. Ophthalmol. 2016; 123(1): 41-111. doi.org/10.1016/j.ophtha.2015.10.053

Mishima H.K., Kiuchi Y., Takamatsu M., Racz P., Bito L.Z. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Ophthalmol. 1997; 41(Suppl 2): 139-44. doi.org/10.1016/s0039-6257(97)80021-5

Orzalesi N., Rossetti L., Invernizzi T., Bottoli A., Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2000; 41(9): 2566-73. doi.org/10.1016/s0002-9394(00)00751-0

Lewis R.A., Gross R.L., Sall K.N., Schiffman R.M., et al. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma. 2010; 19(6): 424-426. doi.org/10.1097/ijg.0b013e3181bdb586

Higginbotham E.J. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol. 2010; 4(1): 1-9. doi.org/10.2147/opth.s6645

Куроедов А.В. Перспективы применению комбинированных антиглаукомных препаратов (обзор литературы). Клиническая офтальмология. 2007; 4: 176-81.

Еричев В.П. Гипотензивная терапия первичной открытоугольной глаукомы фиксированными комбинациями лекарственных средств: метод. рекомендации. Москва: Апрель; 2012.

Centofanti M., Oddone F., Gandolfi S., et al. Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am. J. Ophthalmol. 2010; 150: 575-80. doi.org/10.1016/j.ajo.2010.05.003

Stalmans I., Oddobe F., Cordeiro M. F., Hommer A., et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch. Clin. Exp. Ophthalmol. 2016; 254: 1151-58. doi.org/10.1007/s00417-016-3299-9

Aptel F., Cucherat M., Denis P. Efﬁcacy and tolerability of prostaglandin-timolol ﬁxed combinations: a meta-analysis of randomized clinical trials. Eur. J. Ophthalmol. 2012; 22: 5-18. doi.org/10.5301/ejo.2011.8351

Pfennigsdorf S., de Jong L., Makk S., et al. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 2013; 7: 1219-1225. doi.org/10.2147/opth.s41885

Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26(3): 233-236.

Olthoff C.M, Schouten J.S., Borne B.W. van de, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmol. 2005; 112(6): 953-961. doi.org/10.1016/j.ophtha.2004.12.035

Липатов Д.В., Чиcтяков Т.А., Кузьмин А.Г., Толкачева А.А. Оценка эффективности терапии препаратом Ганфорт у пациентов с вторичной неоваскулярной глаукомой при сахарном диабете. Вестник офтальмологии. 2014; 3: 45-8.

Stalmans I., Sunaric Mégevand G., Cordeiro M.F., Hommer A., et al. Preservative-free treatment in glaucoma: Who, when, and why. Eur. J. Ophthalmol. 2013: 23: 518-525. doi:10.5301/ejo.5000270

Gobbels M., Spitznas M. Inﬂuence of artiﬁcial tears on corneal epithelium in dry eye syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 1989; 227: 139-141. https://doi.org/10.1007/bf02169786

Labbe A., Terry O., Brasnu E., Van W.C., Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012; 31(9): 994-99. doi.org/10.1097/ico.0b013e31823f8cb6

Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma. 2001; 10: 237-49. doi.org/10.1097/00061198-200106000-00017

Breusegem C., Spielberg L., Van Ginderdeuren R. et al. Preoperative nonsteroidal antiinﬂammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmol. 2010; 117: 1324- 30. doi.org/10.1016/j.ophtha.2009.11.038

Rossi G.C., Pasinetti G.M., Scudeller L., et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur. J. Ophthalmol. 2013; 23(3): 296-302. doi.org/10.5301/ejo.5000220

Baudouin C., Renard J.P., Nordmann J.P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2013; 23: 47-54. doi.org/10.5301/ejo.5000181

Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 2007; 17(3): 341-349. doi.org/10.1177/112067210701700311

Pfennigsdorf S., Eschstruth P., Häsemeye S., Feuerhake C., et al. Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice. Clinic. Ophthalmol. 2016; 10: 1837-46. doi.org/10.2147/opth.s106159

Quaranta L., Biagioli E., Riva I, et al. Prostaglandin analogs and timololfixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J. Ocul. Pharmacol. Ther. 2013; 29(4): 382-89. doi.org/10.1089/jop.2012.0186

Cordeiro M.F., Goldberg I., Schiffman R., Bernstein P., Bejanian M. Efficacy of a preservative-free formulation of fixedcombination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients. Clin. Ophthalmol. 2015; 9: 1605-11. doi.org/10.2147/opth.s84163

Goldberg I., Gil Pina R., Lanzagorta-Aresti A., Schiffman R.M., et al. Bimatoprost 0.03%/timolol 0.5% preservativefree ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br. J. Ophthalmol. 2014; 98(7): 926-31. doi.org/10.1136/bjophthalmol-2013-304064

de Jong C., Stolwijk T., Kuppens E., de Keizer R., van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994; 232(4): 221-24. doi.org/10.1007/bf00184009

Bron A., Velasque L., Rebica H., Pouliquen P., et al. Comparaison du timolol sans conservateur et du timolol à délivrance prolongée donnés une fois par jour en association à du latanoprost. [Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost]. J. Fr. Ophthalmol. 2004; 27(9): 971-77. doi.org/10.1016/s0181-5512(04)96251-1 (In French)

Frezzotti P., Fogagnolo P., Haka G., et al. In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmol. 2014; 92(2): 133-40. doi.org/10.1111/aos.12261

Manni G., Centofanti M., Oddone F., Parravano M., Bucci M.G. Interleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am. J. Ophthalmol. 2005; 139(1): 72-7. doi.org/10.1016/j.ajo.2004.08.028

Mastropasqua L., Agnifili L., Fasanella V., et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013; 91(5): 397-405. doi.org/10.1111/aos.12131

Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf). 2008; 242: 7-13. doi.org/10.1111/j.1755-3768.2008.01380.x

Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86(4): 418-23. doi.org/10.1136/bjo.86.4.418

Bron A., Chiambaretta F., Pouliquen P., Rigal D., Rouland J.F. Intérêt de la substitution d’un traitement journalier de 2 instillations de timolol par 1 instillation quotidienne de bêtabloquant non conservé chez des patients présentant un glaucome chronique ou une hypertonie oculaire [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J. Fr. Ophthalmol. 2003; 26(7): 668-74. doi.org/10.1016/s0181-5512(06)73821-9 (In French)

Okabe K., Kimura H., Okabe J., et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 2005; 46(2): 703-8. doi.org/10.1167/iovs.03-0934

Desbenoit N., Schmitz-Afonso I., Baudouin C., et al. Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Anal. Bioanal Chem. 2013; 405(12): 4039-49. https://doi.org/10.1007/s00216-013-6811-7

The authors declare that there are no conflicts of interest present.